Clinical Trial Update: ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study [Phase 2]

View source ↗

Summary

Phase II study results for Zibotentan (ZD4054) in non-small cell lung cancer; the trial completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zibotentan (zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer, Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-06-06